Par Pharmaceutical

Par Pharmaceutical, headquartered in Chestnut Ridge, NY, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life. Par offers differentiated, specialty dosage and sterile injectable drug products and is advancing a R&D pipeline of potential new products.

The recent combination of the Qualitest and Par businesses (known collectively as Par Pharmaceutical) expands Endo's generics business to a top five industry leader. Par Pharmaceutical is an operating company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value.

Type
Subsidiary
Parent Company
Endo International
HQ
Chestnut Ridge, US
Founded
1978
Par Pharmaceutical was founded in 1978 and is headquartered in Chestnut Ridge, US

Par Pharmaceutical Office Locations

Par Pharmaceutical has an office in Chestnut Ridge
Chestnut Ridge, US (HQ)
1 Ram Ridge Rd

Par Pharmaceutical Data and Metrics

Par Pharmaceutical Summary

Founding Date

1978
Par Pharmaceutical is a subsidiary of Endo International

Par Pharmaceutical Financial Metrics

Par Pharmaceutical's revenue was reported to be $246.1 m in FY, 2014
USDFY, 2013FY, 2014

Revenue

246.1 m246.1 m

Operating expense total

75.2 m75.2 m

EBIT

(29.8 m)(29.8 m)

EBIT margin, %

(12%)(12%)

Interest expense

26 m26 m

Interest income

50 k50 k

Income tax expense

(17.7 m)(17.7 m)

Net Income

(32.5 m)(32.5 m)
USDFY, 2013FY, 2014

Cash

130.1 m244.4 m

Accounts Receivable

143.3 m158.7 m

Inventories

117.3 m154.7 m

Current Assets

465.6 m653.1 m

PP&E

127.3 m217.3 m

Goodwill

849.7 m1 b

Total Assets

2.6 b3 b

Accounts Payable

31.2 m80 m

Current Liabilities

259 m277.8 m

Additional Paid-in Capital

686.6 m808.6 m

Retained Earnings

(138.4 m)(243.9 m)

Total Equity

547.4 m561.1 m

Financial Leverage

4.8 x5.4 x
USDFY, 2013FY, 2014

Net Income

(32.5 m)(32.5 m)

Depreciation and Amortization

50.3 m50.3 m

Accounts Receivable

(42 m)(42 m)

Cash From Operating Activities

(28.6 m)(28.6 m)

Capital Expenditures

(10.3 m)(10.3 m)

Cash From Investing Activities

(2 b)(2 b)

Cash From Financing Activities

1.8 b1.8 b

Interest Paid

14 m14 m

Free Cash Flow

(18.3 m)(18.3 m)

Par Pharmaceutical News and Updates

Par Pharmaceutical Company Life and Culture

You may also be interested in